Omenn syndrome is associated with clinical manifestations resembling those of graft-versus-host disease that can lead to organ damage not allowing a safe bridging to hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/JAK2 inhibitor, could be a valuable option to control organ involvement, with a sustained effect also in glucocorticoid-refractory disease.
Use of ruxolitinib to control graft-versus-host-like disease in Omenn syndrome and successfully bridging to HSCT
Merli, Pietro
2021-01-01
Abstract
Omenn syndrome is associated with clinical manifestations resembling those of graft-versus-host disease that can lead to organ damage not allowing a safe bridging to hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/JAK2 inhibitor, could be a valuable option to control organ involvement, with a sustained effect also in glucocorticoid-refractory disease.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
